Список проголосовавших за комментарий " On The Wires<ul><li>EDAP TMS SA (<strong>EDAP</strong>) announced that it has signed an exclusive agreement with the Canadian company LABORIE to distribute their urodynamic diagnostic products in Japan, one of the largest global markets for urology.</li><li>Remark Media, Inc. (<strong>MARK</strong>) announced it has partnered with Alibaba Cloud to provide customers with a new business-to-business (B2B) data solution. Available now, the Enterprise Data Services Solution includes data on tens of millions of businesses in China. It offers real-time risk insights; enterprise development analysis; investor, partner and customer targeting; customized data packages; and more.</li><li>Dextera Surgical Inc. (<strong>DXTR</strong>) announced that Joel Dunning, M.D, Consultant Thoracic Surgeon at James Cook University Hospital in Middlesbrough, UK, demonstrated how Dextera's MicroCutter 5/80 helped enable the removal of a lung lobe through a single small incision. The presentation was made at The Society of Thoracic Surgeons.</li><li>Numerex Corp. (<strong>NMRX</strong>) disclosed in a regulatory filing that Chief Revenue Officer Vincent Costello separated from the company as of January 13, 2017.</li><li>Enteris BioPharma announced the initiation of a feasibility study agreement with Sanofi (<strong>SNY</strong>) to leverage Enteris' proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to develop an oral formulation of one of Sanofi's preclinical stage peptides.</li><li>Elite Pharmaceuticals (<strong>ELTP</strong>) reported the Company received official minutes from its December 21, 2016 end-of-review meeting with the FDA for the New Drug Application for SequestOx. The meeting minutes support a plan to address the issues cited by the FDA in the July 14th Complete Response Letter by modifying the SequestOxTM formulation. Elite will proceed immediately to complete in vitro and in vivo bridging studies required and expects to resubmit the SequestOxTM application later this year. The in vivo studies include bioequivalence and bioavailability fed and fasted studies comparing the modified formulation to the original formulation.</li><li>Lannett Company (<strong>LCI</strong>) announced that the company voluntarily made a $75 mln payment against its existing revolving credit facility.</li></ul>"